Patents by Inventor David A. V. Morton

David A. V. Morton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of respiratory diseases
    Patent number: 8029768
    Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: October 4, 2011
    Assignee: Sosei R&D Ltd.
    Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
  • The Treatment of Respiratory Diseases
    Publication number: 20080220073
    Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
    Type: Application
    Filed: March 14, 2008
    Publication date: September 11, 2008
    Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
  • Treatment of respiratory diseases
    Patent number: 7368104
    Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
    Type: Grant
    Filed: August 24, 2004
    Date of Patent: May 6, 2008
    Assignee: Sosei R&D Ltd.
    Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
  • Treatment of respiratory disease
    Patent number: 7229607
    Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: June 12, 2007
    Assignee: Sosei R&D Ltd
    Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
  • Treatment of respiratory diseases
    Publication number: 20030068280
    Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
    Type: Application
    Filed: October 7, 2002
    Publication date: April 10, 2003
    Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth